VKORC1 and Thromboembolism: In conclusion, we have developed the first pharmacogenetic dosing algorithm for acenocoumarol that includes clinical variables and information about four genes (VKORC1, CYP2C9, CYP4F2 and APOE) and that is able to reasonably predict stable therapeutic doses of acenocoumarol for patients with thromboembolic disease.